Discovery/R&D

1. Oncology Discovery Advances With AbbVie's Steve Davidsen, Ph.D. 10/25/2022

   AbbVie VP of Oncology Discovery Research Steve Davidsen, Ph.D. is a living, breathing timeline of the company's cancer research and development efforts. He got his start with the company— Abbott at the time— way back in 1986. As such, he's charted the adoption of multiple advanced technologies that have contributed to the realization of dozens of molecular weapons in the fight against cancer. On this episode of the Business of Biotech, Dr. Davidsen shares the latest on AbbVie's adoption of computational biology and how it's contributing to discovery and development efficiencies, why he's an AbbVie "lifer," how he manages and motivates a large team of research scientists, and a whole lot more.

2. COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD 7/12/2023

   Chief Operating Officer is arguably the toughest job in the emerging biopharma C-suite. HR, CMC, regulatory affairs, legal, PR, you name it, the COO touches it, and practically everything rolls up to her. This week's episode of the Business of Biotech brings us to a president and COO who's also a mom, a volunteer, and an advocate for diversity and equality in biopharma. That advocacy isn't just lip service, by the way. Here, Rocket Pharmaceuticals' Kinnari Patel, PharmD, shares on the real, practical, replicable steps Rocket takes to build a diverse and equitable work environment, how the fruits of that effort have proven important to the company's success, and where Rocket is taking its high-flying gene therapy act next.

   Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

3. Bioengineering Human Tissue With Humacyte's Dr. Heather Prichard 1/5/2022

   Humacyte COO Dr. Heather Prichard joins the Business of Biotech for a discussion on the company's pipeline of candidates for the repair, replacement, and reconstruction of human vascular vessels. The company recently scaled the production of its implantable bioengineered human tissues from 10 to 200 per day to meet Phase 3 vascular trauma and arteriovenous access trials. On today's episode, Dr. Prichard shares the company's scale-up story and the science and engineering behind a unique approach to regenerative medicine using human tissue.

4. Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D. 10/11/2023

   On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.

5. Fibroblasts In Regenerative Medicine With FibroBiologics' Pete O'Heeron & Dr. Hamid Khoja 6/21/2022

   FibroBiologics Chairman, CEO, & Founder Pete O'Heeron shares the journey that led him from clinical care to biopharma entrepreneurship, and he's joined by Chief Scientific Officer Hamid Khoja, Ph.D., who explains the manufacturing technology that's driving the company's exploitation of fibroblasts to develop regenerative therapies for indications ranging from degenerative disk disease and multiple sclerosis to cancer immunotherapies and therapeutics.

6. Gene Therapies For Ocular Disease With SparingVision's Stéphane Boissel 3/28/2022

   Since assuming the President and CEO role at SparingVision in August 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company'S foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind his vigorous allegiance to internal development.

7. Inhalable mAbs & Vaccines With TFF's Glenn Mattes 12/6/2021

   Glenn Mattes' TFF Pharmaceuticals is looking to break the parenteral barrier by manufacturing biologics — mAbs and vaccines, more specifically — that can be inhaled, rather than injected. It's a timely endeavor, and TFF's business model is a collaborative one that seeks to explore dry powder biologic options through partnership, in addition to its own pipeline. On this episode of the Business of Biotech, the veteran biopharma CEO shares the company's vision and the technology that's bringing it into focus.

8. AI & The Human Genome 2/22/2021

   From his Fellowship at the NIH Human Genome Research Institute to his leadership as CEO at NeuBase Therapeutics, Dr. Dietrich Stephan is recognized as a pioneer in the field of genomic precision medicine. On this episode of The Business of Biotech, Dr. Stephan shares how artificial intelligence is shaping the acceleration of genomic medicine discovery at NeuBase and beyond, with plenty of practical insight on how to adopt and leverage the technology.

9. BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko 3/5/2023

   Elixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final episode in our special series recorded at JPM Week in San Francisco. Life Science Leader Chief Editor Ben Comer joined us for the conversation. We dive deep into Elixirgen's unique, temperature-controlled in-vivo gene expression technology designed to address common cell therapy administration challenges and unwanted, off-target immungenicity effects. Ko also shares progress on the company's ex-vivo candidate EXG-34217, an autologous cell therapy for telomere biology disorders, offers his take on the ever-crowded RNA therapeutics space and how the company is separating itself from the crowd, and much more!

10. How To Hire And Build A Winning Executive Team With Occam Global's Bill Holodnak 8/6/2025

    On this week's Business of Biotech episode, Bill Holodnak, Cofounder and CEO of Occam Global, a life sciences executive recruitment firm (and occasional investor), shares insights from his decades of experience pairing executives with drug development companies, and talks about the psychology of successful biotech leadership.